Alhawari Hussein H, Alshelleh Sameeha, Alhawari Hussam H, Alawwa Izzat Ahmad, AlRyalat Saif Aldeen, Mesmar Ahmad, Ojjoh Khaled, Alzoubi Karem H
Division of Nephrology, Department of Internal Medicine, School of Medicine, The University of Jordan, Jordan.
Division of Endocrinology, Department of Internal Medicine, School of Medicine, The University of Jordan, Jordan.
Biomed Res Int. 2020 May 5;2020:4987547. doi: 10.1155/2020/4987547. eCollection 2020.
Approximately 15 to 33% of all dialysis treatments are complicated by intradialytic hypotension (IDH). In this study, we tested the hypothesis that the intravenous administration of hydrocortisone prior to HD treatment could prevent IDH or at least decrease the drop in the blood pressure resulting from IDH.
This study was approved by our local ethics committee/IRB (2017/87) and by the Jordan Food and Drug Administration (7/clinical/18). Additionally, it is registered on ClinicalTrials.gov (NCT03465007). In this preliminary investigational study, we screened all chronic hemodialysis patients at our clinic who were 18 years of age or older ( = 82) for IDH. There were 14 patients included in the interventional part of this study; patients were given IV hydrocortisone for 3 consecutive HD sessions, followed or preceded by 3 intervention-free sessions where they were given 5 ml of saline as a placebo.
The initial total sample size was 82 patients. The frequency of IDH at our clinic was 24.4%. Fourteen out of the 20 patients who were diagnosed with IDH agreed to enroll in the interventional part of our study. The mean age of the patients in the interventional part of our study was 53.5 years (±10.3). These patients included 5 (35.7%) men and 9 (64.3%) women. Upon comparing the number of hypotensive attacks with and without the hydrocortisone administration, we found a significant difference ( = 0.003) between the hydrocortisone and placebo treatments in which 12 (85.7%) patients had fewer IDH episodes with the hydrocortisone treatment than with placebo.
This preliminary investigational study found that the administration of a stress dose of hydrocortisone prior to hemodialysis could be an effective measure for preventing or minimizing the risk of IDH episodes. Additional prospective studies on this subject are needed. Ruling out adrenal insufficiency in patients diagnosed with IDH is also crucial.
所有透析治疗中约15%至33%会并发透析中低血压(IDH)。在本研究中,我们检验了以下假设:在血液透析(HD)治疗前静脉注射氢化可的松可预防IDH,或至少减少因IDH导致的血压下降。
本研究经我们当地伦理委员会/机构审查委员会(2017/87)及约旦食品药品管理局(7/临床/18)批准。此外,它已在ClinicalTrials.gov上注册(NCT03465007)。在这项初步调查研究中,我们对诊所内所有18岁及以上的慢性血液透析患者(n = 82)进行了IDH筛查。本研究的干预部分纳入了14名患者;患者连续3次HD治疗接受静脉注射氢化可的松,前后各有3次无干预治疗,期间给予5毫升生理盐水作为安慰剂。
初始总样本量为82名患者。我们诊所IDH的发生率为24.4%。20名被诊断为IDH的患者中有14名同意参加我们研究的干预部分。我们研究干预部分患者 的平均年龄为53.5岁(±10.3)。这些患者包括5名(35.7%)男性和9名(64.3%)女性。比较使用和未使用氢化可的松时低血压发作的次数,我们发现氢化可的松治疗与安慰剂治疗之间存在显著差异(P = 0.003),其中12名(85.7%)患者接受氢化可的松治疗时IDH发作次数少于使用安慰剂时。
这项初步调查研究发现,血液透析前给予应激剂量的氢化可的松可能是预防或最小化IDH发作风险的有效措施。对此主题还需要进行更多前瞻性研究。排除被诊断为IDH患者的肾上腺功能不全也至关重要。